Sélectionner une page

FOSTERING NEXT GENERATION OF LIVING DRUGS

Center for IPS cell therapy

We focus on the development of Cell drugs with high potential of anti-tumoral activities and high immune compatibility for many patients

.

We believe in the potential of IPSC as an unlimited source for next generation ATMPs to answer unmeet needs

We are investing in Building the French Allogeneic & Universal IPSC Bank & Developing “off-the-shelf” IPSC-Base Therapeutic Product to overcome limitations of Autologous Therapies

Our first Mission is to build the French National Bank of GMP IPSC

The reason why of a national bank is to :

  • minimise cost, logistics, redundancy & to increase the chance to finding rare HLA-matched donors
  • Guarantee high standard of quality control & ethical applications

A French center for IPS cell based therapies

CITHERA is developing the national bank of clinical grade pluripotent stem cells and new cellular biomedicines to fight cancer. This Center of the University of Paris Saclay, Inserm and the University of Evry at Genopole, is directed by Professor Annelise Bennaceur Griscelli and it is attached to the INSERM UA09 Unit ‘Malignant and therapeutic stem cell models’ under the direction of Professor Ali Turhan in Villejuif, near Paris . CITHERA was awarded as Industrial integrator  by the « Grand Défi » from the  Government recovery plan innovation council.

CITHERA is the platform that coordinates the INGESTEM infrastructure of the medical and industrial exploitation sector of IPSC stem cells and its mission is to build the clinical grade iPSC bank with the know-how acquired since the derivation of the first ESC lines in 2006 then IPSC in 2008.

CiTHERA, founding member of the MAGENTA industrial integrator

Novel immunotherapy potential of iPSC

Novel immunotherapy potential of iPSC: INSERM U1310 reports the major potential of IPSC as cancer vaccines read the article here : https://pubmed.ncbi.nlm.nih.gov/34957134/

New label for INSERM U935 /UA9

After evaluation by the INSERM scientific committee CSS2 (Cancer), INSERM U935 has been renewed as a monothematic Inserm Unit UMRS 1310 under the direction of Pr. Ali Turhan. The Unit, in close collaboration with CITHERA is developing cancer and leukemia models for...

New label for INSERM U935 /UA9

New label for INSERM U935 /UA9: After evaluation by the INSERM scientific committee CSS2 (Cancer), INSERM U935 has been renewed as a monothematic Inserm Unit UMRS 1310 under the direction of Pr. Ali Turhan. The Unit, in close collaboration with CITHERA is developing...

Reach Us

UMS45 CiTHERA – 28 rue Henri Desbruères 91100 Corbeil-Essonnes

Leave A Message